EndoForce™
The future of venous anastomosis during vascular graft implantation using an endovascular approach.
EndoForce™
The future of venous anastomosis during vascular graft implantation using an endovascular approach.
The future of venous anastomosis during vascular graft implantation using an endovascular approach.
The future of venous anastomosis during vascular graft implantation using an endovascular approach.
Phraxis is a forward-thinking medical device company, based out of Minneapolis, MN currently developing a novel endovascular coaxial connector for venous anastomosis.
The investigational EndoForce™ is a patented endovascular implant for coaxial, endovascular anastomosis of a vein to an arteriovenous graft for hemodialysis.
The EndoForce™ was designed to provide an alternative, less traumatic endovascular venous anastomosis that may ameliorate the clinical challenges associated with a sutured anastomosis.
Our experienced leadership team excels in general management, product development, and clinical and regulatory affairs. With a proven track record of guiding medical device companies to successful commercialization, we are committed to making a lasting impact in healthcare.
The EndoForce™ Venous Anastomotic Connector was developed to provide an endovascular method for the attachment of an arteriovenous graft to a vein in the upper extremity to enable hemodialysis for patients with end stage renal disease.
Minneapolis, MN information@phraxis.com
The EndoForce™ is an investigational device limited by federal (United States) law to investigational use.
Copyright © 2023 Phraxis - All Rights Reserved.